<DOC>
	<DOCNO>NCT01346865</DOCNO>
	<brief_summary>The DECREASE-PCI trial prospective , randomize , placebo control , double-blind , phase 4 study evaluate efficacy safety triple anti-platelet therapy compare dual antiplatelet therapy patient treat DES Coronary Artery Disease . The primary objective study compare safety efficacy triple antiplatelet therapy versus dual ( standard ) antiplatelet therapy patient treat drug-eluting stent ( DES ) implantation treatment coronary artery disease .</brief_summary>
	<brief_title>Drug-Eluting Stenting Followed Cilostazol tREAtment Reduces SErious Adverse Cardiac Events ( DECREASE-PCI )</brief_title>
	<detailed_description>Use drug-eluting stent ( DES ) reduce incidence restenosis rate need repeat revascularization compare use bare metal stent ( BMS ) . Therefore , DES implantation default strategy treatment coronary artery disease . However , despite use DES , restenosis , subsequent repeat revascularization , associate cardiac event ( stent thrombosis , myocardial infarction ) remain significant clinical problem routine practice , especially complex lesion subset . 2110 patient receive successful dug elute stent implantation enrol 21 center Korea . Patients meet inclusion criterion without exclusion criterion agree participate trial randomized 1:1 ) triple therapy ( Aspirin+Clopidogrel +Cilostazol ) b ) dual therapy group ( Aspirin+ Clopidogrel +Placebo ) . All patient blindly assign cilostazol 100mg ( 1tablet bid ) match placebo ( 1tablet bid ) 1:1 ratio prescribe 1 year .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<criteria>1 . Clinical 1 . Patients angina document ischemia patient document silent ischemia 2 . Patients eligible successfully apply DES implantation 3 . Age &gt; 18 year 4 . Signed write informed consent form prior study entry 2 . Angiographic 1 . De novo lesion restenotic lesion 2 . Percent diameter stenosis â‰¥50 % 3 . Reference vessel size 2.5 mm visual estimation 1 . History bleed diathesis coagulopathy ( e.g . current use NSAIDs , Upper GI bleed recent 6 month ) 2 . Pregnancy lactation ( woman childbearing potential ) 3 . Known hypersensitivity contraindication contrast agent , heparin , eluteddrug stent 4 . Limited lifeexpectancy ( less 1 year ) due combine serious disease 5 . Characteristics lesion 1 ) Left main disease 2 ) Graft vessel 6 . Hematological disease ( Neutropenia &lt; 3000/mm3 , Thrombocytopenia &lt; 100,000/mm3 ) 7 . Hepatic dysfunction , liver enzyme ( ALT AST ) elevation 3 time normal 8 . Renal dysfunction , creatinine 2.0mg/dL 9 . Contraindication aspirin , clopidogrel cilostazol 10 . Stroke ( ischemic hemorrhagic ) transient ischemic attack ( TIA ) within 6 month . 11 . Planned major surgery within next 6 month need discontinue antiplatelet therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>triple anti-platelet therapy</keyword>
	<keyword>dual antiplatelet therapy</keyword>
	<keyword>DES</keyword>
	<keyword>Coronary Artery Disease</keyword>
</DOC>